Skip to content

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis. This study has been completed. Sponsor: Amgen. Collaborator:. The majority of diagnosed patients have plaque psoriasis, and about 20 have moderate to severe disease. 27 The objective of this study was to assess the efficacy and safety of the addition of methotrexate to etanercept compared with etanercept monotherapy in patients with moderate to severe plaque psoriasis using a randomized, double-blind, placebo-controlled, multicentre design. Placebo-controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects With Moderate to Severe Plaque Psoriasis.

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis 2The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis – NCT01001208-Waterloo – 003(Clinical Trial 491727). Source: DGNews Addition of Methotrexate to Etanercept Significantly Improves Treatment Response in Patients With Moderate to Severe Psoriasis: Presented at EADV By Jenny Powers LISBON, Portugal — October 25, 2011 — More patients with moderate to severe psoriasis had faster improvement of their psoriasis, as measured by a 75 reduction in Psoriasis Area and Severity (PASI 75) scores at 12 weeks after combination treatment with methotrexate and etanercept than with etanercept monotherapy, according to a study presented here at the 20th Congress of the European Academy of Dermatology and Venereology (EADV). Presentation title: Efficacy and Safety of Adding Methotrexate to Etanercept Versus Etanercept Monotherapy in Adults With Moderate to Severe Plaque Psoriasis. The addition of etanercept to the treatment regimen of psoriasis patients not adequately controlled on methotrexate monotherapy results in significant clinical improvement. There is good evidence for both the efficacy and safety of methotrexate and etanercept combination therapy in psoriasis.

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. Psoriasis, tumor necrosis factor inhibitors, efficacy, safety, psoriatic arthritis. 3 Clinicians may wish to consider adding methotrexate to adalimumab, especially in patients with severe psoriasis and PsA who have failed other therapies. Secondary efficacy analyses included psoriasis area and severity index, American College of Rheumatology responses, psoriatic arthritis response criteria, and improvement in joint and tendon disease manifestations. No new safety signals were seen in either etanercept treatment group, and no significant difference in the safety profiles was observed.

The Efficacy And Safety Of Adding Methotrexate To Etanercept In Psoriasis

Recent data suggest that biological therapies have efficacy and safety profiles suitable for the long-term treatment of patients with moderate to severe psoriasis. Conventional nonbiological therapies for moderate to severe psoriasis, such as cyclosporine, methotrexate, and phototherapy, have proved effective in suppressing symptoms; and many dermatologists have at least a decade of experience using these treatment modalities 21. ETANERCEPT Results for etanercept 25 or 50 mg twice weekly for 24 weeks 18. To compare the clinical efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis (RA). Nab,R. Pedersen,Add Enbrel or Replace Methotrexate Study Investigators. Aetna considers biological therapies adalimumab (Humira), apremilast (Otezla), etanercept (Enbrel), infliximab (Remicade), secukinumab (Cosentyx), and ustekinumab (Stelara) medically necessary for adults aged 18 years and older with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy when the following selection criteria are met:. Other systemic treatments for psoriasis include methotrexate or cyclosporine. Clinical efficacy and safety of anti-fibrotic treatments (e.g., imatinib) await confirmation. In addition, small studies have been published with successful therapeutic intervention using alefacept, visilizumab or anakinra, but controlled trials are needed. Data are limited on the efficacy of biologic agents other than infliximab for the treatment of erythrodermic psoriasis. However, high quality studies on the efficacy and safety of therapies for psoriasis in children are limited. In addition, patients who were transitioned from methotrexate to infliximab fared better than those who switched to methotrexate from infliximab; 73 versus 11 percent achieved 75 percent improvement in the PASI score. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study.

Enbrel (etanercept)

The aim of this systematic review is to evaluate efficacy and safety of off-label dosing regimens (dose escalation, dose reduction, and interrupted treatment) with etanercept, adalimumab, infliximab, ustekinumab, and alefacept for psoriasis treatment. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: Efficacy and safety results from an open-label study. In contrast, in psoriatic arthritis, the addition of methotrexate to anti-tumour necrosis factor-alpha therapy does not enhance efficacy in either the skin or joints. Key Words: acitretin, adalimumab, alefacept, biologics, calcipotriol, combination therapy, cyclosporine, etanercept, infliximab, methotrexate, phototherapy, psoriasis. Some efficacy and safety data in psoriasis are available for combination therapy with adalimumab, alefacept, etanercept, and infliximab, but not for ustekinumab. Among several clinical psoriasis phenotypes, chronic plaque psoriasis is the most frequent, accounting for all but 10 percent of cases. One of the main research gaps identified in this meta-analysis was the lack of comparative effectiveness and safety data for biologic versus nonbiologic systemic treatments for moderate-to-severe plaque psoriasis. We also manually searched references from included studies and previously conducted systematic reviews, adding relevant citations to the literature base. Infection rate did not differ between adalimumab and methotrexate (low strength of evidence).